医学
经皮
感染性心内膜炎
分流(医疗)
外科
栓塞
房室传导阻滞
心导管术
心脏病学
内科学
心脏传导阻滞
心电图
作者
Anoosh Esmaeili,K. Behnke-Hall,Roland Schrewe,Dietmar Schranz
出处
期刊:Congenital Heart Disease
[Computers, Materials and Continua (Tech Science Press)]
日期:2018-12-18
卷期号:14 (3): 389-395
被引量:13
摘要
Aim The purpose of this study is to describe the special aspects of perimembranous ventricular septal defects (pmVSD) closure by utilizing Amplatzer Duct Occluder II (ADO II) devices with a rational request for bigger ADO-II sizes, based on our experience in transcatheter device closure of pmVSD. Methods and Results At our institution, placement of an ADO II device was used in 15 patients with pmVSD; the patients’ age ranged between 6 months and 20 years. The indications for closure were CHF (n = 4), hemodynamically significant shunt (n = 7), tricuspid regurgitation (n = 3), and high risk for infective endocarditis (n = 2), respectively. The location of the VSD was infracristal in 13 patients, supracristal in 1, and a postsurgical Gerbode VSD in another one. Implantation of the device was successfully performed without embolization, any evidence of an AV block, or other conductance abnormalities during implantation and follow-up in the mean of 2.5 years (range 2 months-6.5 years). Conclusions Transcatheter closure of a pmVSD with ADO II is feasible in all pediatric and young adult age groups, by considering the device diameter limitations. The off-label use of ADO II implantation seems to be safe for VSDs closure up to 6 mm of size and feasible for various locations including unusual morphology such as postsurgical Gerbode defect.
科研通智能强力驱动
Strongly Powered by AbleSci AI